



ABN 53 075 582 740

02 December 2021

ASX Market Announcements
ASX Limited
Level 4
Stock Exchange Centre
20 Bridge Street
SYDNEY NSW 2000

Dear Sir/Madam

RESULTS OF ANNUAL GENERAL MEETING

In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act, we advise details of the resolutions and the proxies received in respect of each resolution as set out in the attached proxy summary.

FOR FURTHER INFORMATION PLEASE CONTACT:

Ms Suzanne Irwin
Company Secretary
+61 8 8150 7400
CoSec@bionomics.com.au

About Bionomics Limited

Bionomics (ASX:BNO, OTCQB:BNOEF) is a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system ("CNS") disorders with high unmet medical need. Bionomics is advancing its lead product candidate, BNC210, an oral proprietary selective negative allosteric modulator of the $\alpha 7$ nicotinic acetylcholine receptor, for the acute treatment of Social Anxiety Disorder ("SAD") and chronic treatment of Post-Traumatic Stress Disorder ("PTSD"). Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc (known as MSD outside the United States and Canada) with two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer's disease and other central nervous system conditions.

www.bionomics.com.au

BIONOMICS LIMITED
ANNUAL GENERAL MEETING - DECEMBER 2021
Thursday, 02 December 2021
Results of Meeting

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

Resolution details		Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Result
Resolution	Resolution Type	For	Against	Proxy's Discretion	Abstain	For	Against	Abstain*	Carried / Not Carried
1 Adoption of Remuneration Report	Ordinary	197,414,804 95.16%	2,589,099 1.25%	7,457,075 3.59%	433,668	202,341,765 96.99%	6,289,825 3.01%	2,420,117	Carried
2 Election of Mr Peter Miles Davies as a Director	Ordinary	198,700,080 94.86%	1,920,539 0.92%	8,838,099 4.22%	280,019	206,994,514 97.36%	5,621,265 2.64%	280,019	Carried
3 Re-election of Mr David Wilson as a Director	Ordinary	198,653,304 94.84%	2,004,902 0.96%	8,800,965 4.20%	279,566	209,611,330 98.59%	3,004,902 1.41%	279,566	Carried
4 Approval of appointment of Auditor	Ordinary	200,130,755 95.49%	491,744 0.23%	8,977,248 4.28%	138,990	212,265,064 99.77%	491,744 0.23%	138,990	Carried
5 Adoption of the New Constitution	Special	194,981,136 94.84%	1,809,964 0.88%	8,800,965 4.28%	4,146,672	206,939,162 99.13%	1,809,964 0.87%	4,146,672	Carried
6 Ratification of prior issue of 110,287,131 Shares	Ordinary	195,527,673 93.32%	5,185,961 2.48%	8,787,631 4.20%	237,472	201,785,190 94.89%	10,873,136 5.11%	237,472	Carried
7 Ratification of prior issue of 21,137,380 Shares	Ordinary	195,354,817 93.22%	5,342,188 2.55%	8,848,417 4.23%	193,315	205,339,846 96.54%	7,362,637 3.46%	193,315	Carried
8 Issue shares - US Nasdaq initial public offering	Ordinary	43,042,926 80.17%	1,817,596 3.38%	8,833,628 16.45%	156,044,587	53,047,166 96.69%	1,817,596 3.31%	158,031,036	Carried
9 Approve issue of shares - US Nasdaq IPO to Apeiron	Ordinary	198,966,229 94.94%	1,718,566 0.82%	8,891,158 4.24%	162,784	207,313,722 97.45%	5,419,292 2.55%	162,784	Carried
10 Approve issue of shares - US Nasdaq IPO to BVF	Ordinary	43,172,759 79.87%	2,100,219 3.88%	8,787,631 16.25%	155,678,128	51,416,725 89.86%	5,800,945 10.14%	155,678,128	Carried
11 Proposed Employment Issue to Dr Errol De Souza	Ordinary	197,178,256 94.34%	3,031,734 1.45%	8,801,465 4.21%	727,282	203,415,607 96.80%	6,732,460 3.20%	2,747,731	Carried
12 Proposed IPO Issue to Dr Errol De Souza	Ordinary	197,019,383 94.25%	3,149,423 1.51%	8,853,971 4.24%	715,960	203,306,773 95.83%	8,839,065 4.17%	749,960	Carried
13 Approve termination benefits to Dr Errol De Souza	Ordinary	192,603,997 92.15%	7,577,353 3.63%	8,812,391 4.22%	378,298	200,836,256 94.67%	11,314,546 5.33%	378,298	Carried
14 Approval of Bionomics Limited Employee Equity Plan	Ordinary	198,454,197 95.06%	1,409,770 0.68%	8,889,830 4.26%	984,940	208,514,639 99.33%	1,409,770 0.67%	2,971,389	Carried
15 Approval of 10% Placement Facility	Special	194,126,805 92.70%	6,496,525 3.10%	8,785,503 4.20%	329,904	200,348,194 94.27%	12,183,700 5.73%	363,904	Carried

* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.